How many days do you hold osimertinib during or around SBRT for oligometastatic EGFR mutated advanced lung cancer?

Topics: Lung Cancer • Radiation Oncology • Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer • EGFR+

Does the site of treatment factor into your decision?

Answer from: Medical Oncologist at Community Practice

This a great question and a common clinical scenario that we are all confronted with. Stereotactic body radiation therapy (SBRT) is being increasingly used for oligometastatic progression of EGFR mutant NSCLC. The theoretical risk of combining EGFR inhibitors and radiation therapy would be an enhanc...

Comments

Radiation Oncologist at Mount Carmel Medical Center
Agree, the original protocol of SINDAS study (pres...

Radiation Oncologist at Princess Margaret Hospital at University of Toronto
Anything that goes beyond 3 weeks is a bit worriso...

Answer from: Radiation Oncologist at Academic Institution

As far as I know, there is not a clear answer for this situation. After discussion with our medical oncology team, we currently tend to hold osimertinib for about 5-7 days prior to and after RT based on similar logic as Dr. @Afshin Dowlati above. Anecdotally, even after holding osimertini...

Related Questions